FDA NDC Directory · JSON-LD · Markdown

Exelon

NDC 0078-0502 · HUMAN PRESCRIPTION DRUG · PATCH, EXTENDED RELEASE

Generic namerivastigmine
Labeler / ManufacturerNovartis Pharmaceuticals Corporation
Marketing categoryNew Drug Application (innovator) · App NDA022083
Dosage form / routePATCH, EXTENDED RELEASE · TRANSDERMAL
Active ingredientsRIVASTIGMINE (9.5 mg/24h)
Marketing started20070706
Marketing ended20261231
Package count1

External sources

Source: openFDA. Public-domain (CC0).